ModelEdge

Oramed Pharmaceuticals Inc.
ORMP
Filing Type10-K
Filing Date3/26/2025
Updated3/27/25, 3:00 PM

Filing

10-K
Earnings Release

Exhibits

10-KFY 2024
EX-3.2FIFTH AMENDED AND RESTATED BY-LAWS, ADOPTED EFFECTIVE MARCH 27, 2025
EX-3.3FIFTH AMENDED AND RESTATED BY-LAWS, ADOPTED EFFECTIVE MARCH 27, 2025 (MARKED COPY)
EX-4.2DESCRIPTION OF SECURITIES
EX-10.72AMENDMENT, DATED NOVEMBER 7, 2024, TO EMPLOYMENT AGREEMENT BY AND BETWEEN ORAMED LTD. AND NADAV KIDRON, ENTERED INTO AS OF NOVEMBER 1, 2022
EX-10.73AMENDMENT, DATED NOVEMBER 7, 2024, TO EMPLOYMENT AGREEMENT BY AND BETWEEN ORAMED LTD. AND NADAV KIDRON, ENTERED INTO AS OF NOVEMBER 1, 2022
EX-10.74AMENDMENT, DATED NOVEMBER 7, 2024, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED LTD. AND KNRY, LTD., ENTERED INTO AS OF JULY 1, 2008, FOR THE SERVICES OF MIRIAM KIDRON
EX-19.1ORAMED PHARMACEUTICALS INC. INSIDER TRADING POLICY
EX-21.1SUBSIDIARIES
EX-23.1CONSENT OF KESSELMAN & KESSELMAN, CERTIFIED PUBLIC ACCOUNTANTS (ISR.), A MEMBER FIRM OF PRICEWATERHOUSECOOPERS INTERNATIONAL LIMITED, AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.
EX-31.1CERTIFICATION
EX-31.2CERTIFICATION
EX-32.1CERTIFICATION
EX-32.2CERTIFICATION
GRAPHICGraphic
GRAPHICGraphic